Xencor

contact sitemap home

Products

• PRODUCTS

• Pipeline
• Clinical Trials

• XmAb™ Antibody Therapeutics

  • XmAb™2513
  • XmAb™5574
  • XmAb™5483
  • XmAb™5871
  • XmAb™ Pipeline Candidates
• XPro™ Protein Therapeutics

XmAb™5871

XmAb™5871 is a humanized monoclonal antibody that targets the antigens CD19 and CD32b for the treatment of autoimmune diseases using a uniquely selective dual-targeting mechanism for B-cell inhibition. This novel therapeutic combines a high-affinity CD19-binding variable domain with a Xencor XmAb Fc domain that selectively engages the inhibitory CD32b receptor.

RELATED LINKS

• XmAb™ Technology
• Partnering opportunities

Location Careers Events Publications Articles Press Releases

Copyright © 2005 Xencor, Inc.   All rights reserved.   Designed by